ENLIE Pharmaceutical JSCHSTC:BCP 25 EBIT per Share is ₫ as of . 20. GuruFocus rates HSTC:BCP with a GF Score™ of 25/100. Among 811 Drug Manufacturers companies, ENLIE Pharmaceutical JSC ranks worse than 123304.44% on this metric.
ENLIE Pharmaceutical JSC's EBIT per Share for the
six
months ended in . 20 was ₫0.00.
ENLIE Pharmaceutical JSC does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in . 20.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ENLIE Pharmaceutical JSC's EBIT per Share or its related term are showing as below:
HSTC:BCP's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.8 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
ENLIE Pharmaceutical JSC (HSTC:BCP) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ENLIE Pharmaceutical JSC EBIT per Share Related Terms
ENLIE Pharmaceutical JSC EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENLIE Pharmaceutical JSC (HSTC:BCP) has a EBIT per Share of ₫ as of . 20. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ENLIE Pharmaceutical JSC and its competitors. According to the industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 811 companies in the Drug Manufacturers industry.
Is ENLIE Pharmaceutical JSC's EBIT per Share too high?
ENLIE Pharmaceutical JSC's current EBIT per Share is ₫. Based on the distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ENLIE Pharmaceutical JSC has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENLIE Pharmaceutical JSC's EBIT per Share compare to ?
According to the Drug Manufacturers industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 811 companies for EBIT per Share. This places ENLIE Pharmaceutical JSC in the lower half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ENLIE Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENLIE Pharmaceutical JSC's current EBIT per Share is ₫. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENLIE Pharmaceutical JSC stock overvalued right now?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a current EBIT per Share of ₫. The current EBIT per Share is ₫. ENLIE Pharmaceutical JSC's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ENLIE Pharmaceutical JSC (HSTC:BCP), the current EBIT per Share is ₫ as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENLIE Pharmaceutical JSC is engaged in the production and trading of pharmaceuticals, medical supplies, cosmetics, foods, and functional foods. It is also engaged in the wholesale of other installation materials and equipment in the construction.
25GF Score
Get the complete analysis for HSTC:BCP
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:BCP has been successfully added to your 